ATG／ALG联合环孢素A治疗老年重型再生障碍性贫血16例疗效及安全性评估
目的评估老年（1〉60岁）重型再生障碍性贫血（sAA）患者接受兔抗人胸腺细胞球蛋白（rATG）／猪抗人淋巴细胞球蛋白（pALG）联合环孢素A（CsA）的强烈免疫抑制治疗（IST）方案的疗效和安全性。方法回顾性分析16例老年SAA患者接受rATG／pALG＋CsA治疗的血液学反应率和安全性，分析影响疗效的相关因素。结果16例患者男13例，女3例，中位年龄63．5（60～79）岁，其中60～69岁13例，I〉70岁3例；SAA患者9例，极重型AA（VSAA）患者7例；9例患者接受rATG治疗，7例患者接受pALG治疗。16例患者均顺利完成rATG／pALG治疗，治疗后早期死亡2例（12．5％），均...
Saved in:
| Published in | Zhōnghuá xuèyèxué zázhì Vol. 37; no. 7; pp. 607 - 610 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese English |
| Published |
No. 288, Nanjing road, Heping district, Tianjin
中国医学科学院、北京协和医学院血液学研究所、血液病医院, 天津,300020
01.07.2016
Editorial office of Chinese Journal of Hematology |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0253-2727 2707-9740 |
| DOI | 10.3760/cma.j.issn.0253-2727.2016.07.013 |
Cover
Loading…
| Abstract | 目的评估老年（1〉60岁）重型再生障碍性贫血（sAA）患者接受兔抗人胸腺细胞球蛋白（rATG）／猪抗人淋巴细胞球蛋白（pALG）联合环孢素A（CsA）的强烈免疫抑制治疗（IST）方案的疗效和安全性。方法回顾性分析16例老年SAA患者接受rATG／pALG＋CsA治疗的血液学反应率和安全性，分析影响疗效的相关因素。结果16例患者男13例，女3例，中位年龄63．5（60～79）岁，其中60～69岁13例，I〉70岁3例；SAA患者9例，极重型AA（VSAA）患者7例；9例患者接受rATG治疗，7例患者接受pALG治疗。16例患者均顺利完成rATG／pALG治疗，治疗后早期死亡2例（12．5％），均为VSAA患者（2／7，28．6％）；IST后6个月9例（56．3％）患者获得血液学反应，5例无治疗反应。9例应用rATG的患者有2例获得血液学反应，7例应用pALG患者全部获得血液学反应，差异有统计学意义（22．2％对100．0％，P=0．003）。rATG／pALG＋CsA相关不良反应轻微，经对症治疗好转。结论老年SAA接受rATG／pALG联合CsA的IST方案仍可获较好血液学反应；VSAA患者早期死亡率高，治疗风险大；pALG治疗老年SAA疗效可能优于rATG。 |
|---|---|
| AbstractList | 目的 评估老年(≥60岁)重型再生障碍性贫血(SAA)患者接受兔抗人胸腺细胞球蛋白(rATG)/猪抗人淋巴细胞球蛋白(pALG)联合环孢素A(CsA)的强烈免疫抑制治疗(IST)方案的疗效和安全性.方法 回顾性分析16例老年SAA患者接受rATG/pALG+CsA治疗的血液学反应率和安全性,分析影响疗效的相关因素.结果 16例患者男13例,女3例,中位年龄63.5(60～79)岁,其中60～69岁13例,≥70岁3例;SAA患者9例,极重型AA(VSAA)患者7例;9例患者接受rATG治疗,7例患者接受pALG治疗.16例患者均顺利完成rATG/pALG治疗,治疗后早期死亡2例(12.5％),均为VSAA患者(2/7,28.6％);IST后6个月9例(56.3％)患者获得血液学反应,5例无治疗反应.9例应用rATG的患者有2例获得血液学反应,7例应用pALG患者全部获得血液学反应,差异有统计学意义(22.2％对100.0％,P=0.003).rATG/pALG+CsA相关不良反应轻微,经对症治疗好转.结论 老年SAA接受rATG/pALG联合CsA的IST方案仍可获较好血液学反应;VSAA患者早期死亡率高,治疗风险大;pALG治疗老年SAA疗效可能优于rATG. 目的评估老年（1〉60岁）重型再生障碍性贫血（sAA）患者接受兔抗人胸腺细胞球蛋白（rATG）／猪抗人淋巴细胞球蛋白（pALG）联合环孢素A（CsA）的强烈免疫抑制治疗（IST）方案的疗效和安全性。方法回顾性分析16例老年SAA患者接受rATG／pALG＋CsA治疗的血液学反应率和安全性，分析影响疗效的相关因素。结果16例患者男13例，女3例，中位年龄63．5（60～79）岁，其中60～69岁13例，I〉70岁3例；SAA患者9例，极重型AA（VSAA）患者7例；9例患者接受rATG治疗，7例患者接受pALG治疗。16例患者均顺利完成rATG／pALG治疗，治疗后早期死亡2例（12．5％），均为VSAA患者（2／7，28．6％）；IST后6个月9例（56．3％）患者获得血液学反应，5例无治疗反应。9例应用rATG的患者有2例获得血液学反应，7例应用pALG患者全部获得血液学反应，差异有统计学意义（22．2％对100．0％，P=0．003）。rATG／pALG＋CsA相关不良反应轻微，经对症治疗好转。结论老年SAA接受rATG／pALG联合CsA的IST方案仍可获较好血液学反应；VSAA患者早期死亡率高，治疗风险大；pALG治疗老年SAA疗效可能优于rATG。 |
| Abstract_FL | Objective To evaluate the efficacy and safety of intensive immunosupressive therapy (IST) with antithymocyte/antilymphocyte globulin plus cyclosporine A in the treatment of older patients (≥60 years) with severe aplastic anemia (SAA).Methods The hematologic response and safety of sixteen older SAA patients treated with IST regimen in our hospital were retrospectively analyzed,and the factors affecting response were also explored.Results A total of 16 older SAA patients were involved,the median age was 63.5 (60-79) years.Among them,7 were VSAA and 9 were SAA;9 patients received Rabbit anti-human thymocyte globulin (rATG),and 7 patients porcine anti-human lymphocyte globulin (pALG).Two patients died within 3 months after IST;at the 6 months after IST,9 patients achieved hematology response and 5 patients had no response;overall response rate was 56.3％.Two (22％) of the 9 patients treated with rATG achieved hematology response;However,all 7 patients (100.0％) treated with pALG achieved hematology response,rATG/pALG associated adverse reactions were mild and easily managed.Conclusion The older patients with SAA could still benefit from IST consisting of standard dose rATG/pALG with CsA,and the patients with VSAA had worse prognosis,pALG was inferior to rATG as a first treatment for SAA. |
| Author | 李建平 杨文睿 李园 叶蕾 周康 井丽萍 李洋 彭广新 宋琳 张凤奎 张莉 |
| AuthorAffiliation | 中国医学科学院、北京协和医学院血液学研究所、血液病医院,天津300020 |
| AuthorAffiliation_xml | – name: 中国医学科学院、北京协和医学院血液学研究所、血液病医院, 天津,300020 – name: 300020 天津，中国医学科学院、北京协和医学院血液学研究所、血液病医院 Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China |
| Author_xml | – sequence: 1 fullname: 李建平 杨文睿 李园 叶蕾 周康 井丽萍 李洋 彭广新 宋琳 张凤奎 张莉 |
| BookMark | eNpVkEFrE0EYhgdpMUn1T3gQL7vOzuzMZC9CKDYVAr2kx7LMzE6SDc1smm1r4ikBq2lD2h6qgoi2vSiIppRcSoO_pptNTv6FbogtePoO78PzfrwZsKADrQB4ZkETMwqfyxo3q6YfhtqEiGADMcRMBC1qQmZCCz8AacQgMxxmwwWQvmdSIBOGVQjthLUfghRiBJMsxWmwkSvm_46OcoX8pHMSHXfjw0H06zwenubGl9fxx0-Tdie6Gk7f96OvvehdPz75Nv38JT7vj9vfJ8Ofk7O2RW_-9BJw_KEbHR1Ev_ejvR-zcPD2ZnTxCCyW-GaoHv-7S2B95WVxedUorOVfLecKhrQsjA2MKCcO9xBSSgrPI1TazJNcCsGVTbOCOjahDrc8ZSkhoBQlIRAqMcRxltg2XgIv5t76jqgpTyq93eCbbr3h13ij5Qbcd_9PtF9xy8GuyzAlEGYTwdO54DXXJa7LbjXYaejkZfdNpdlqziaGLBk4AZ_MQVkJdHnLT9C7FkodAh2MCb4Fpemd4g |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. 2016年版权归中华医学会所有 Copyright © 2016 by Chinese Medical Association 2016 |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: 2016年版权归中华医学会所有 Copyright © 2016 by Chinese Medical Association 2016 |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ 5PM |
| DOI | 10.3760/cma.j.issn.0253-2727.2016.07.013 |
| DatabaseName | 维普期刊资源整合服务平台 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| DocumentTitleAlternate | Antithymocyte/Antilymphocyte globulin plus cyclosporine A therapy for the treatment of older patients with severe aplastic anemia |
| DocumentTitle_FL | Antithymocyte/Antilymphocyte globulin plus cyclosporine A therapy for the treatment of older patients with severe aplastic anemia |
| EISSN | 2707-9740 |
| EndPage | 610 |
| ExternalDocumentID | PMC7365008 zhxyx201607013 669509335 |
| GroupedDBID | --- -05 2B. 2C~ 2RA 92F 92I 92L ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 F5P OK1 RPM TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI PSX 5PM |
| ID | FETCH-LOGICAL-c1133-326a59ad22eecbdd56c47dcacbbae468b694569a1de1ebb0cbfbb22f72a385443 |
| ISSN | 0253-2727 |
| IngestDate | Thu Aug 21 18:15:29 EDT 2025 Thu May 29 04:03:11 EDT 2025 Wed Feb 14 10:18:06 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Keywords | 贫血,再生障碍性 老年人 免疫抑制法 Anemia,aplastic Immunosupressive therapy Older |
| Language | Chinese English |
| License | This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c1133-326a59ad22eecbdd56c47dcacbbae468b694569a1de1ebb0cbfbb22f72a385443 |
| Notes | Objective To evaluate the efficacy and safety of intensive immunosupressive therapy （IST） with antithymocyte/antilymphocyte globulin plus cyclosporine A in the treatment of older patients （I〉60 years） with severe aplastic anemia （SAA）. Methods The hematologic response and safety of sixteen older SAA patients treated with IST regimen in our hospital were retrospectively analyzed, and the factors affecting response were also explored. Results A total of 16 older SAA patients were involved, the median age was 63.5 （60-79） years. Among them, 7 were VSAA and 9 were SAA; 9 patients received Rabbit anti-human thymocyte globulin （rATG）, and 7 patients porcine anti-human lymphocyte globulin （pALG）. Two patients died within 3 months after IST; at the 6 months after IST, 9 patients achieved hematology response and 5 patients had no response; overall response rate was 56.3%. Two （22%） of the 9 patients treated with rATG achieved hematology response; However, all 7 patients （100.0%） treated with pALG achieved hematology r |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7365008 |
| PMID | 27535863 |
| PageCount | 4 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7365008 wanfang_journals_zhxyx201607013 chongqing_primary_669509335 |
| PublicationCentury | 2000 |
| PublicationDate | 20160701 |
| PublicationDateYYYYMMDD | 2016-07-01 |
| PublicationDate_xml | – month: 7 year: 2016 text: 20160701 day: 1 |
| PublicationDecade | 2010 |
| PublicationPlace | No. 288, Nanjing road, Heping district, Tianjin |
| PublicationPlace_xml | – name: No. 288, Nanjing road, Heping district, Tianjin |
| PublicationTitle | Zhōnghuá xuèyèxué zázhì |
| PublicationTitleAlternate | Chinese Journal of Hematology |
| PublicationTitle_FL | Chinese Journal of Hematology |
| PublicationYear | 2016 |
| Publisher | 中国医学科学院、北京协和医学院血液学研究所、血液病医院, 天津,300020 Editorial office of Chinese Journal of Hematology |
| Publisher_xml | – name: 中国医学科学院、北京协和医学院血液学研究所、血液病医院, 天津,300020 – name: Editorial office of Chinese Journal of Hematology |
| SSID | ssj0042014 ssib051368330 ssib017477332 ssib001103535 ssib058574913 |
| Score | 2.0726473 |
| Snippet | ... 目的 评估老年(≥60岁)重型再生障碍性贫血(SAA)患者接受兔抗人胸腺细胞球蛋白(rATG)/猪抗人淋巴细胞球蛋白(pALG)联合环孢素A(CsA)的强烈免疫抑制治疗(IST)方案的疗效和安全性.方法... |
| SourceID | pubmedcentral wanfang chongqing |
| SourceType | Open Access Repository Aggregation Database Publisher |
| StartPage | 607 |
| SubjectTerms | 免疫抑制法 老年人 论著 贫血，再生障碍性 |
| Title | ATG／ALG联合环孢素A治疗老年重型再生障碍性贫血16例疗效及安全性评估 |
| URI | http://lib.cqvip.com/qk/93752X/201607/669509335.html https://d.wanfangdata.com.cn/periodical/zhxyx201607013 https://pubmed.ncbi.nlm.nih.gov/PMC7365008 |
| Volume | 37 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3JahRBtAkRxYsoKsa45GCBl0l6ra46ds30JIh6SiDgYehtMgpOXBKMOSXgEg1RD1FBxCUXBdGI5CKKX5POTP7C96qX6ZkEo16K4tWrt1ZX1euufqUo52DZ4YFnwPMdeToEKF5U4mGolQJYqjUe-KYvrwO6dJmOTZgXJq3Jvv6pwqml2Rl_OJjf9b-S__EqwMCv-JfsP3g2JwoAqIN_oQQPQ_lXPnbGRzEfwsVR4jLYEhJuEtciXCWMEdcmzCVOFSFOhTg6QoRJHNUhLiVCJ0IgiFPCbdlfRRKALTjiuZwwIFGRFF3CBFYYlRAbOfEq4nCH8DJCgAE2UaTjSILITGDF0QAI0btrEpFQytlCaUlpoawS5khpAYdLCNRZF0lQh5mSTpkItbixlkCGmmLHCuqecZbqSo1TU1DJF3AkRFQJzxfjrMWVLYIIJ7OI0YOSSAZqgJVQnwoQ2pUKF6ST8zJVFMQB6UB14RZfu2g0P6KbPChdWgEhkahXlr7LlbHROlwrQMAvXLrc6LgVeqHFTdTJKWdmkuOD69i6C-Wczh9MCdxVOfKgwqVmFP2HyDn3nd1tFAYc3GGa8YJnXlI3kRx2gIoFUEN-zy4sXLpllHQ7yfmQrbJJap90NrELSyZNbj1Od180OeTcu7Dj0S14oILr3vA1yWQ4Z4LHM5MEvMlPzT3p0-cbc3fndJlHUcXbrffpEE-qPa_1YA9sWJ24wdIMyoxOXA0htW3Kz_nJFs8EejIvXSbDAeV8KuTIXiJiDpfGdHPqJuxMdx7E3n_Ha9a95lRhjzt-WDmUBqdDTjLTHFH65htHlSswy4zAHNNeXI2fLbWerMef11ob75ytbz9aL162Fxbj7xvbD1fiN8vxg5XW6tvtV69baytbCx_aG5_a7xc0uvlrGRC3ni_FTx_HXx7F9z9i4_q9zZ9fjykTVXe8PFZKr2QpBZpmGCUI9jyLe6GuR1Hgh6FFA9MOAy_wfS8yKfMph4iMe1oYaZHvq4Ff931dr9u6ZzBMtXlc6W9ON6MTyhA17EBjqgcxY2TqEaYRMzU7qPtUi5gRqgPKYG6o2o0k9U6NUm7hO1hrQLG7TJdjYLr87pbm1YZMm28bEI2qbEA5mxq5lk7lt2vdg-TknhiDysHOnHBK6Z-5NRudhuBkxj8jB9Zv7SD1lg |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ATG%2FALG%E8%81%94%E5%90%88%E7%8E%AF%E5%AD%A2%E7%B4%A0A%E6%B2%BB%E7%96%97%E8%80%81%E5%B9%B4%E9%87%8D%E5%9E%8B%E5%86%8D%E7%94%9F%E9%9A%9C%E7%A2%8D%E6%80%A7%E8%B4%AB%E8%A1%8016%E4%BE%8B%E7%96%97%E6%95%88%E5%8F%8A%E5%AE%89%E5%85%A8%E6%80%A7%E8%AF%84%E4%BC%B0&rft.jtitle=%E4%B8%AD%E5%8D%8E%E8%A1%80%E6%B6%B2%E5%AD%A6%E6%9D%82%E5%BF%97&rft.au=%E6%9D%8E%E5%BB%BA%E5%B9%B3&rft.au=%E6%9D%A8%E6%96%87%E7%9D%BF&rft.au=%E6%9D%8E%E5%9B%AD&rft.au=%E5%8F%B6%E8%95%BE&rft.date=2016-07-01&rft.pub=%E4%B8%AD%E5%9B%BD%E5%8C%BB%E5%AD%A6%E7%A7%91%E5%AD%A6%E9%99%A2%E3%80%81%E5%8C%97%E4%BA%AC%E5%8D%8F%E5%92%8C%E5%8C%BB%E5%AD%A6%E9%99%A2%E8%A1%80%E6%B6%B2%E5%AD%A6%E7%A0%94%E7%A9%B6%E6%89%80%E3%80%81%E8%A1%80%E6%B6%B2%E7%97%85%E5%8C%BB%E9%99%A2%2C+%E5%A4%A9%E6%B4%A5%2C300020&rft.issn=0253-2727&rft.volume=37&rft.issue=7&rft.spage=607&rft.epage=610&rft_id=info:doi/10.3760%2Fcma.j.issn.0253-2727.2016.07.013&rft.externalDocID=zhxyx201607013 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F93752X%2F93752X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzhxyx%2Fzhxyx.jpg |